ImmuneMed, Inc. focuses on harnessing the human immune system to combat infectious diseases, emphasizing the potential of utilizing the body's natural defenses as a fundamental approach to treatment. The company is actively developing burfiralimab, an antiviral drug candidate, which is derived from their research on the Virus Suppressing Factor (VSF). This innovative approach aims to provide therapeutic solutions for various viral infections, including chronic hepatitis B and COVID-19, with ongoing clinical trials demonstrating promising results in inhibiting viral infections.

In addition to antiviral drug development, ImmuneMed is engaged in creating diagnostic tools and vaccines for infectious diseases. Their research includes the development of a dengue vaccine that enhances specificity through the recombination of dengue virus antigens, as well as rapid diagnostic kits for diseases such as leptospirosis and typhoid fever. These projects reflect the company's commitment to advancing medical technology and improving public health outcomes through innovative research and development initiatives.

South Korea

Clinical-stage Biopharmaceutical Company developing burfiralimab against Chronic hepatitis B and autoimmune diseases. Also Antibodies and small molecules are in the pipeline for oncological and immunological disorders.

ImmuneMed

Company Details